Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common blood pressure drug lower uric acid in kids with kidney problems?

NCT ID NCT05402397

Disease control Sponsor: Hospital General de Niños Pedro de Elizalde Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether losartan, a blood pressure medicine, can lower uric acid levels in children with proteinuric nephropathies (kidney disease with protein in urine). Forty children already taking enalapril were randomly assigned to receive either losartan or continue enalapril for 30 days, then switched after a washout period. Researchers measured uric acid in blood and urine to see if losartan made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Losartan potassium
What this could lead to
If it works, this could show that losartan helps manage uric acid levels in children with kidney disease, offering a potential additional treatment option.
What could go wrong
This is a small, early-phase study with only 40 children, and it focuses on a lab marker (uric acid) rather than long-term health outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Jul 2022

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children with poteinuric nephropathies already treated with enalapril under our care. * Age between 3 and 12 years. * Normal blood pressure. Exclusion Criteria: * Patients with high blood pressure. * Post menarche female patients. * Patients with hypouricemia (\< 2 mg/dL). * Patients treated with diuretics. * Patients with absolute or relative contraindications to receive RAAS antagonists (glomerular filtration \< 30 ml/min/1,73 m2, serum potassium \> 5,5 mEq/L). * Patients with active rheumatic diseases. * Patients treated with dual blockade of the RAAS (enalapril +losartan). * Patients treated with calcineurin inhibitors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uric acid nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute urate nephropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uric acid nephropathy

Contacts and locations

Locations

  • HGNPE

    CABA, Buenos Aires F.D., 1417, Argentina